Like many other celebrities in the weeks leading up to the presidential election, influencer and TV personality Tana Mongeau is encouraging her social media followers to vote. But she’s doing it a little differently.
Like many other celebrities in the weeks leading up to the presidential election, influencer and TV personality Tana Mongeau is encouraging her social media followers to vote. But she’s doing it a little differently.
The "United States Plant Protein Business and Investment Opportunities (2018-2027) Insight Series - White Space/Gap Analysis, Product Strategy, Innovation and Brand Share Analysis, Competitive Landscape, Market Size Across 50+ Segments - Updated in Q3, 2020" report has been added to ResearchAndMarkets.com's offering.
Stock futures pointed sharply lower Monday morning as new data showed a jump in COVID-19 cases in both the U.S. and Europe. Restrictions tightened across major countries overseas, raising the specter of a further pullback in business operations and deeper anchor on global economic activity.
ROCHESTER, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Monday, November 9, 2020 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2020. OptimizeRx management will host the call, followed by a question and answer period. As earlier reported, the company expects to report record revenue for the quarter of more than $10.0 million, up over 100% from the same year-ago quarter, along with positive non-GAAP net income.On the call, management will review how this growth has been driven organically by a combination of enterprise deals and tactical programs, as the company’s life science customers increasingly see the value in transparent access to physicians and patients provided by the OptimizeRx Digital Health Platform.The full financial results for the quarter will be issued in a press release prior to the call.Conference Call Information Date: Monday, November 9, 2020 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Toll-free dial-in number: 1-800-430-8332 International dial-in number: 1-323-347-3277 Conference ID: 9818386Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 30, 2020, as well as available for replay via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.Toll-free replay number: 1-844-512-2921 International replay number: 1-412-317-6671 Replay ID: 9818386About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.OptimizeRx Contact Doug Baker, CFO Tel (248) 651-6568 (x807) email@example.com Media Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 firstname.lastname@example.orgInvestor Relations Contact Ron Both, CMA Tel (949) 432-7557 email@example.com
Harley-Davidson’s third-quarter earnings were likely hampered by the Covid-19 pandemic. The company has pushed back 2021 models from its usual late summer launch to early next year.
Wabtec Corporation (NYSE: WAB) today announced the appointment of Nicole Theophilus to Executive Vice President and Chief Human Resources Officer effective immediately. Theophilus will be responsible for leading Wabtec’s global HR organization, including talent management, leadership development and learning, and compensation and benefits. Theophilus succeeds Scott Wahlstrom who will be retiring from Wabtec after nearly 30 years of dedicated service.
SQI Diagnostics Inc. (the "Company" or "SQI") (TSX-V: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today updated the Company's clinical development progress for its three novel Covid-19 tests, highlighted by confirmation from the U.S. FDA that Emergency Use Authorization (EUA) submission is acceptable for all three COVID diagnostic tests. SQI is accelerating the clinical development of its direct-to-consumer COVID-19 HOME Antibody Test, its COVID-19 RALI-dx™ Severity Triage Test and its COVID-19 RALI-fast™ Severity Triage Point-of-Care (POC) Test.
HOLLAND, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Macatawa Bank Corporation (Nasdaq: MCBC) (the "Company" or "Macatawa") today announced that its Board of Directors has declared a quarterly cash dividend of $0.08 per share on its common stock to be paid on November 25, 2020 to shareholders of record on November 10, 2020. Despite the economic challenges posed by the COVID-19 pandemic, Macatawa has continued to perform well. This dividend reflects the strong financial condition and earnings performance of the Company. About Macatawa Bank Corporation Macatawa Bank Corporation is the bank holding company for its wholly-owned subsidiary bank, Macatawa Bank. Headquartered in Holland, Mich., Macatawa Bank offers a full range of banking, retail and commercial lending, wealth management and ecommerce services to individuals, businesses and governmental entities from a network of 26 full-service branches located throughout communities in Kent, Ottawa and northern Allegan counties. The bank is recognized for its local management team and decision making, along with providing customers excellent service, a rewarding experience and superior financial products. Macatawa Bank has been recognized for the past ten consecutive years as one of “West Michigan’s 101 Best and Brightest Companies to Work For”. For more information, visit www.macatawabank.com.CAUTIONARY STATEMENT: This press release contains forward-looking statements that are based on management's current beliefs, expectations, assumptions, estimates, plans and intentions. Such statements are based upon current beliefs and expectations and involve substantial risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. The declaration and payment of each future dividend to common shareholders will be considered by the Board of Directors in its discretion and will depend on a number of factors, including our financial condition, liquidity, profits, anticipated profitability and economic conditions within our markets. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions ("risk factors") that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Therefore, actual results and outcomes may materially differ from what may be expressed in or implied by such forward-looking statements. Macatawa Bank Corporation does not undertake to update forward-looking statements to reflect the impact of circumstances or events that may arise after the date of the forward-looking statements.Risk factors include, but are not limited to, the risk factors described in "Item 1A - Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2019 and in “Item 1A – Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These and other factors are representative of the risk factors that may emerge and could cause a difference between an ultimate actual outcome and a preceding forward-looking statement. CONTACT: Contact: Jon Swets, CFO 616-494-7645
The Global Mechanical Seals Market will grow by USD 1.12 bn during 2020-2024
HCA Healthcare, Inc. (NYSE: HCA) today announced its completed financial and operating results for the third quarter ended September 30, 2020.
WASHINGTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Omar Aguilar as a Senior Managing Director in the Corporate Finance & Restructuring segment in Houston. Mr. Aguilar further enhances FTI Consulting’s Business Transformation offering in the Energy, Power & Products industry practice, where he will lead overall performance improvement efforts, as well as focus on the consumer products and industrials sectors. He provides innovative and lasting solutions to clients at the CEO and board levels globally.“Omar is a widely recognized cost management and business transformation expert,” said Carlyn Taylor, Global Co-Leader of the Corporate Finance & Restructuring segment and Leader of the Business Transformation practice at FTI Consulting. “His depth of expertise in multiple industry sectors, eminence and relationships in the marketplace will help us as we continue to accelerate our strategic investment in our business transformation capabilities to help clients navigate complex challenges and opportunities.”Mr. Aguilar’s areas of expertise include strategic cost transformation, margin improvement, turnarounds, disruptive cost strategies and business model transformations. His appointment comes as companies continue to face near and mid-term challenges from the COVID-19 pandemic, requiring them to restructure operations and transform their businesses to ensure sustainable growth.“At its core, our work is about helping clients turn a negative into a positive, and they need that support now more than ever,” said Mr. Aguilar. “The scale, size and breadth of FTI Consulting’s platform, focused on serving clients when their more important issues are at stake, as well as the investments in talent that the firm is making, will allow us to continue to work with clients on that mission as we grow FTI Consulting’s Business Transformation practice.”Prior to joining FTI Consulting, Mr. Aguilar was a senior Partner at Deloitte Consulting, where he led the global strategic cost transformation market offering from 2015 to 2020. From 2011 to 2016, he was Deloitte Consulting’s Americas Regional Strategy and Operations Leader, focusing on Latin America. Prior to that, he was the Enterprise Cost Management Practice Leader for U.S. Consulting.Mr. Aguilar joined Deloitte in 2004 following its acquisition of Gunn Partners, where he was the firm’s managing director. Before his consulting career, Mr. Aguilar spent 10 years at American Electric Power, where he held engineering and management positions at its Nuclear Generation Group.About FTI Consulting FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 5,800 employees located in 27 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.35 billion in revenues during fiscal year 2019. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.FTI Consulting, Inc. 555 12th Street NW Washington, DC 20004 +1.202.312.9100Investor Contact: Mollie Hawkes +1.617.747.1791 firstname.lastname@example.orgMedia Contact: Matthew Bashalany +1.617.897.1545 email@example.com
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the presentation of preclinical data on the specific inhibition of NRG1 fusion signaling by seribantumab, a HER3 monoclonal antibody, at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Odintsov et al., 2020). The data support the scientific rationale for the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. The CRESTONE study is currently enrolling at sites across the US. Details on the CRESTONE study have recently been presented at both the AACR Virtual Special Conference: Pancreatic Cancer (Bendell et al., 2020) and the North American Conference on Lung Cancer (Spigel et al., 2020).
MONTREAL, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. (“Gilead”) for the commercialization of AmBisome® (liposomal amphotericin B) in Brazil. The agreement will be effective starting January 1, 2021. “We’re excited to renew this established partnership and we’re grateful for Gilead’s continued confidence in the Knight team” said Samira Sakhia, President and Chief Operating Officer of Knight. “Our Brazilian team launched AmBisome in Brazil over 20 years ago and we look forward to continuing the great work they have been doing with patients and physicians.”“The signing of this new agreement extends the long-standing collaboration between Gilead and Grupo Biotoscana (“GBT”) and validates Knight’s valuation of the GBT acquisition” said Amal Khouri, VP Business Development of Knight.“Gilead highly values the ongoing partnership with GBT to help address medical needs in Brazil,” said Ahmed Afifi, Vice President and Region Head Latin America at Gilead Sciences. “With this new agreement, we look forward to continuing our collaboration with the expanded GBT/Knight team to help enable access to AmBisome to Brazilian patients.”About AmBisome® AmBisome® (liposomal amphotericin B) is a non-pyrogenic lyophilized sterile intravenous infusion of liposomal amphotericin B. It is indicated (1) for the treatment of severe deep mycotic infections and/or endemic and opportunistic systemic mycosis, (2) for the treatment of fever of undetermined origin (FUO) in neutropenic patients where FUO is defined as persistent fever, which does not respond to antibiotic therapy after 96 hours and is highly indicative of a systemic fungal infection, (3) as the primary therapy of visceral leishmaniasis in immunocompetent patients. AmBisome® is a registered trademark of Gilead Sciences, Inc. and is licensed from Gilead and has been part of Knight’s Brazilian affiliate’s portfolio for over twenty years. Knight’s affiliates are responsible for distribution and commercial activities for AmBisome® in Brazil as well as Bolivia, Paraguay and Peru.About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pan-American (ex-US) specialty pharmaceutical company focused on developing, acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.Forward-Looking StatementThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. Contact Information for Knight:Knight Therapeutics Inc. Samira Sakhia President and Chief Operating Officer T: 514.484.4483 F: 514-481-4116 Email: firstname.lastname@example.org Website: www.gud-knight.comKnight Therapeutics Inc. Arvind Utchanah Chief Financial Officer T. 514.484.4483 F. 514.481.4116 Email: email@example.com Website: www.gud-knight.com
Sage Science and Universal Sequencing Technology announced a distribution agreement to improve access to long-range genomic info from short-read data.
Agree Realty Corporation (NYSE: ADC) (the "Company") today updated the percentage of its portfolio's annualized base rents generated from investment grade retailers or parent entities thereof based on Tractor Supply Company's receipt of public issuer ratings of BBB from S&P Global Ratings and Baa1 from Moody's Investors Service on October 21, 2020.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.
Westport, CT, Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), announced the halting of its signal finding Phase 2 trial, “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination with Intravenous Remdesivir in Adult Patients with Advanced Coronavirus Disease 2019 (COVID-19)”.After the implementation of a protocol amendment that expanded the size of the trial from 40 to 80 hospitalized COVID-19 patients, and that limited enrollment to seriously ill patients, (NIAID Grade 3, who required high flow, high concentration oxygen to maintain adequate oxygenation) the Safety Monitoring Committee (SMC) was unblinded for safety reasons since these patients are at higher risk for dying from their disease. At the time of the most recent review of the data by the SMC, 44 patients had been enrolled in the trial of whom 42 had received study drug (either merimepodib solution or matching placebo). This most recent review of the data documented all 22 Grade 4 patients were discharged from the hospital and did not relapse during the 37 day follow-up period. However, patients who were NIAID Grade 3 patients (n = 20) at the time of enrollment had markedly different outcomes. Specifically, the unblinded SMC detected an imbalance in survival rates in these NIAID Grade 3 patients between the placebo and merimepodib making it unlikely that the trial would meet its primary safety endpoints. The company has therefore elected to stop enrollment into the clinical trial. Patients will be followed as per the protocol for safety monitoring; however, no further study drug treatments will be administered.At this time, the Company does not intend to further develop merimepodib. However, the Company will see if other parties are interested in acquiring or licensing merimepodib.About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 firstname.lastname@example.org 203-409-5444, x133
TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products announced today that the Company received approval from the Colombian Agricultural Institute (“ICA”) for the registration of its nine psychoactive Tetrahydrocannabinol (“THC”) dominant strains with the national cultivar registry. Blueberries today also announced that Mr. Camilo Villalba has resigned as the Chief Executive Officer (“CEO”) of the Company due to unforeseen personal reasons. Blueberries would like to thank Mr. Villalba for his service and significant contribution to the Company. Mr. Villalba will be available to provide consulting services to Blueberries."It is with great regret that I have to stand down from Blueberries so early in our company's evolution. I see such enormous potential both with the company and medicinal cannabis sector. However, some extremely unanticipated circumstances have arisen that have forced my hand, and I am unable to carry on. We have achieved tremendous milestones so far, and I would like to thank the board for having given me this opportunity."The board is pleased to announce that is has appointed Mr. Christian Toro as the Interim CEO of the Company effective October 23, 2020. Mr. Toro will continue to act as the Executive Chairman of Blueberries in addition to assuming the Interim CEO role. With the ongoing Covid-19 crisis, the board has decided it would be inappropriate to appoint a new CEO at present. Instead, the focus will be on reducing costs and preserving capital.Earlier this year, Blueberries implemented extensive cost saving measures of reducing administrative, capital and operational expenditures and preserving working capital to optimize its cost structure and focus on revenue bringing activities. Due to the ongoing impact of the Covid-19 pandemic, Blueberries is continuing its cost saving measures until revenues from sales commence. About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:Christian Toro, Chairman and Chief Executive Officer email@example.com Tel: +57 (310) 219 9911Ian Atacan, Chief Financial Officer firstname.lastname@example.org Tel : +1 (416) 562 3220Cautionary Note Regarding Forward-Looking Information This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products in 2020, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones in 2020 as contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Presenting at the BIO Europe Digital Conference October 26-29, 2020VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to provide an update on the development of its licensed Berubicin drug candidate in celebration of National Brain Cancer Day on October 24, 2020 in Canada.WPD is conducting research related to the development of Berubicin, as a novel drug candidate in glioblastoma multiforme (“GBM”) therapy for children and adult patients, as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. The main goal of the project is to implement a multicenter pediatric phase I clinical trial to determine the maximum tolerated dose and also clinical trials in adults, in order to confirm the efficacy of Berubicin. Berubicin is an innovative drug candidate, licensed from CNS Pharmaceuticals, Inc. in certain territories, being studied to determine its effects on brain cancer cells that are resistant to temozolomide, which today is used as the standard chemotherapeutic. The project also provides for preclinical testing to determine the possible use of Berubicin in combination with temozolomide and with other compounds being developed by WPD and by other companies as candidates for anticancer drugs.Last week, WPD met with Worldwide Clinical Trials, a world-renowned Contract Research Organization engaged to coordinate and supervise the start-up of WPD’s Phase 1 and 2 clinical trials on Berubicin. The discussions indicated that the Berubicin adult trial is expected to commence in February 2021 and the children multicenter pediatric phase I clinical trial later in 2021. About 60% of the program budget is expected to be refunded by a grant already awarded to WPD by The National Center for Research and Development based in Poland under the European Union’s Smart Growth Operational Program.BIO Europe Digital ConferenceWPD is also pleased to announce that the Company has been invited to present at the Bio-Europe Digital conference October 26-29, 2020. BIO Europe is a leading European Pharmaceuticals event with 4,000 executives from over 60 countries. Due to COVID-19, The BIO Europe conference will be virtual this year and attendees will have access to on demand panels on BD&L, Finance, Therapeutic Areas and up-to-the-minute spotlight topics. For more information on the conference, visit: https://informaconnect.com/bioeurope/.About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.On Behalf of the Board‘Mariusz Olejniczak’Mariusz Olejniczak CEO, WDP PharmaceuticalsContact: Investor Relations Email: email@example.com Tel: 604-428-7050Web: www.wpdpharmaceuticals.com Cautionary Statements: Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that our Berubicin adult trial is expected to commence in February 2021 and the children multicenter pediatric phase I clinical trial later in 2020; that about 60% of the program budget will be refunded by a grant and that WPD’s drug candidates could be developed into novel treatments for cancer. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.
VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company revolutionizing the delivery of healthcare to patients, is pleased to provide an update on its North American expansion plans with the closing of the acquisition of Benchmark Systems Inc. (“Benchmark”) and the closing of the acquisition of a U.S. based chronic care clinic in Mississippi. Benchmark Acquisition Close CloudMD, through its subsidiary, CloudMD Holdings Corporation (Delaware) Inc., has closed its previously announced acquisition of a majority interest in Benchmark Systems Inc. (“Benchmark”), a leading cloud-based provider of fully integrated solutions that automate healthcare workflow processes including revenue management, practice management and electronic records management. CloudMD purchased 87.5% of Benchmark from its parent company and global healthcare and AI leader, AntWorks Inc. (“AntWorks”). AntWorks has retained a 12.5% equity stake and remains a strategic partner for CloudMD both in the U.S. and globally. The purchase of Benchmark is immediately accretive to CloudMD and provides a number of opportunities for optimization to drive further revenue. In the fiscal year ending March 31, 2020, Benchmark generated approximately US$4.9 million in revenues with earnings before interest, taxes, depreciation and amortization (EBITDA) margins of 13%. Approximately 80% of revenue was SaaS based, recurring revenue.Benchmark is an innovative cloud-based, health technology company that has integrated medical practice solutions including patient portals, personal health records, scheduling solutions, billing, messaging, eFax, computerized physician order entry (CPOE) and prescription scripting. Benchmark has a national U.S. network of 200 clients, 800 physicians, with 5.5 million patient charts across 35 states. On average, Benchmark processes approximately $2.5 million in charges (gross) each month.As CloudMD continues to embark on its U.S. expansion, the acquisition of Benchmark strengthens CloudMD’s digital footprint across North America. The acquisition also brings cross selling synergies across Benchmark’s 200 clinics and its geographical footprint in 35 states. Benchmark’s suite of software solutions provides CloudMD with significant distribution channels into the U.S. and integration opportunities for its other virtual care solutions such as those offered through Cloud Practice, Snapclarity and iMD Health. With Benchmark’s experienced leadership team, and seamless workflow process, CloudMD will not only benefit from its extensive geographic reach and client commitment, but also the expertise of developing SAAS systems that support medical practitioners while complying with specific state requirements.Terms of the Agreement In consideration for the purchase of 87.5% of the outstanding securities of Benchmark, CloudMD has agreed to pay shareholders aggregate consideration of US$4,375,000 payable in cash, subject to working capital adjustment.U.S. Chronic Care Clinic Acquisition Close CloudMD also announces that it has closed the previously announced acquisition to acquire 100% of a U.S. based medical clinic serving chronic care patients as a part of its broader strategy for entering the U.S. market with its comprehensive suite of telehealth products.The acquisition is an important and strategic part of CloudMD’s cross-border expansion plan into the United States. One of the key goals for CloudMD is to start providing a single comprehensive stop for longitudinal healthcare for chronic and complex care patients in the U.S. These patients often have multiple concurrent diseases such as diabetes, hypertension, vascular and heart disease. The opportunity for expansion with this acquisition is significant, as in the U.S alone, 90% of the $3.5 Trillion spent annually on health care is spent on chronic pain and mental health issues (Source: CDC). CloudMD’s integrated telehealth technology will be used in the clinic practice to provide patient centric, continuity of care.The clinic is managed by Dr. Fred Roh and Curtis Gibson. Dr. Roh has over 30 years’ experience in the U.S. healthcare market having been founder of Healthcare Networks of America, LLC, a 15,000 member physician organization that provides services to 24 million patients across the U.S. Using CloudMD’s telehealth platform, patient management software and virtual kiosk carts and kits, Dr. Roh will also help with expansion plans to build a network of telehealth powered satellite clinics covering large areas of underserviced areas across the U.S. Curtis Gibson oversees the management of the clinic in Mississippi and will be involved in the expansion of CloudMD services within the southeastern U.S. Mr. Gibson has over 30 years’ experience in investment banking and business development for medical clinics.Terms of Agreement In consideration for the purchase of a 100% interest of the U.S. based medical clinic, CloudMD has agreed to a cash payment to the shareholders, along with additional working capital as required.About CloudMD Software & Services CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.ON BEHALF OF THE BOARD OF DIRECTORS“Dr. Essam Hamza, MD" Chief Executive Officer FOR ADDITIONAL INFORMATION CONTACT:Julia Becker investors.cloudmd.ca Email: firstname.lastname@example.orgForward Looking StatementsThis news release contains forward-looking statements that are based on CloudMD’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA](“BioCardia” or the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the publication of data from the Company’s initial open-label roll-in cohort that served as the precursor for the Company’s ongoing CardiAMP™ Heart Failure (HF) Phase 3 clinical trial. Published in the International Journal of Cardiology, the study data shows that CardiAMP is a well-tolerated treatment in heart failure patients and demonstrated improved distance in six-minute exercise testing at six months and a trend toward improvement at one year. This 10-patient cohort was the feasibility test for the currently enrolling CardiAMP HF Phase 3 clinical trial.The study, entitled “Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort,” followed 10 patients with chronic post-heart attack heart failure (NYHA class II and III) who underwent a 5 ml bone marrow aspiration to determine cell potency using the patented CardiAMP cell potency assay followed by CardiAMP cell therapy, consisting of bone marrow mononuclear cell (BM MNC) enrichment and transendocardial injection of 200 million BM MNCs, at a subsequent single point-of-care visit. The study followed those subjects for 12 months and showed no serious adverse events related to bone marrow or cell delivery. Importantly, improvement at six months was observed in Six Minute Walk distance (+47.8 meters, p=0.01) and trended to improvement at 12 months (+46.4 meters, p=0.06). Echocardiographic data substantiated the improved performance of patients, as better contractility was seen of the heart.“These results surpassed what we saw in our Phase 2 trial in similar NYHA Class I, II, and III ischemic heart failure patients. Utilizing our cell potency assay is an important component of the CardiAMP treatment process, as it is the potency of the patients’ own cells that facilitates the regeneration and, therefore, the therapy. The results for these 10 patients are a meaningful marker for the heart failure community as a whole, and we believe it bodes well for our larger trial, for which these first patients laid the groundwork,” said BioCardia Chief Medical Officer Eric Duckers, M.D., Ph.D. “Our current CardiAMP HF trial is currently enrolling, and we anticipate full enrollment as early as the fourth quarter of 2021. In the meantime, we expect to receive the results from our data and safety monitoring board (DSMB) review by December 15, 2020.”The published paper also reported 12-month trends toward improvement in a variety of cardiac functions, including left ventricular ejection fraction and recruitment of previously akinetic left ventricular wall segments. The 10-patient cohort also displayed trends toward improvement of NYHA heart failure functional class and overall quality of life. The International Journal of Cardiology article is currently available online here and is expected to be available in print in the coming weeks.About BioCardia BioCardia, Inc., headquartered in San Carlos, California, is developing autologous and allogenic cell-based therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company has also developed a portfolio of approved enabling products that optimize delivery of its cell therapies.Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, the intended outcomes of and enrollment in our trials, the efficacy and safety of our products and therapies, and statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, obtaining regulatory approvals, and the ability to raise the additional funding needed to continue to pursue BioCardia’s product development plans. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled “Risk Factors” therein.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Media Contact: Michelle McAdam, Chronic Communications, Inc. email@example.com (310) 902-1274Investor Contact: David McClung, Chief Financial Officer Investors@BioCardia.com (650) 226-0120